• Core Scientific, Inc. has reported its fourth‑quarter and full‑year 2025 results, with quarterly revenue of US$79.76 million and net income of US$215.96 million, alongside lower full‑year revenue of US$319.02 million and a full‑year net loss of US$288.62 million.
• The shift from a prior net loss to quarterly profitability, supported by reduced impairments of property, plant and equipment to US$11.36 million, underscores the operational impact of Core Scientific’s move toward AI‑focused data center infrastructure.
• Now we’ll examine how Core Scientific’s return to quarterly profitability may influence its earlier investment narrative centered on AI infrastructure expansion.

Find 45 companies with promising cash flow potential yet trading below their fair value.

Core Scientific Investment Narrative Recap

To own Core Scientific today, you need to believe its pivot from Bitcoin mining to AI and high performance computing hosting can offset lower legacy revenue and support a more sustainable earnings profile. The Q4 2025 swing to US$215.96 million in net income, despite lower quarterly and full year revenue, strengthens the near term catalyst around AI infrastructure execution. However, it does little to change the biggest current risk, which is still the heavy reliance on CoreWeave and a small number of large, capital intensive contracts.

Among recent developments, the decision by Chairman Jordan Levy not to stand for re election at the 2026 Annual Meeting matters in the context of governance and execution risk. With Core Scientific emerging from restructuring and reshaping itself around AI data centers, board continuity and oversight are important to how effectively it manages large contracts, capital spending, and the transition away from mining, especially as profitability has been volatile across recent quarters.

Yet behind the return to quarterly profitability, investors should also be aware that...

Core Scientific's narrative projects $1.5 billion revenue and $334.4 million earnings by 2028. This requires 60.9% yearly revenue growth and an earnings increase of about $930 million from -$595.2 million today.

Uncover how Core Scientific's forecasts yield a $26.82 fair value, a 63% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue might still need to climb toward about US$1.3 billion and earnings to roughly US$33.7 million by 2028, so this profit swing could either ease their concerns about heavy client concentration risk or prompt them to reassess whether those more pessimistic expectations still fit the evolving Core Scientific story.

Explore 3 other fair value estimates on Core Scientific - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Core Scientific research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Core Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Core Scientific's overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.